These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 26041287)

  • 1. H3K27 Demethylation at the Proviral Promoter Sensitizes Latent HIV to the Effects of Vorinostat in Ex Vivo Cultures of Resting CD4+ T Cells.
    Tripathy MK; McManamy ME; Burch BD; Archin NM; Margolis DM
    J Virol; 2015 Aug; 89(16):8392-405. PubMed ID: 26041287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple Histone Lysine Methyltransferases Are Required for the Establishment and Maintenance of HIV-1 Latency.
    Nguyen K; Das B; Dobrowolski C; Karn J
    mBio; 2017 Feb; 8(1):. PubMed ID: 28246360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cellular Gene Modulation of HIV-Infected CD4 T Cells in Response to Serial Treatment with the Histone Deacetylase Inhibitor Vorinostat.
    Maxwell JW; Falcinelli SD; Nefedov A; Dorfmeier C; Wu G; Dewey M; Webber AL; Archin NM; Margolis DM; Hazuda DJ; Barnard RJO; Howell BJ
    J Virol; 2020 Jun; 94(13):. PubMed ID: 32295913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic silencing of HIV-1 by the histone H3 lysine 27 methyltransferase enhancer of Zeste 2.
    Friedman J; Cho WK; Chu CK; Keedy KS; Archin NM; Margolis DM; Karn J
    J Virol; 2011 Sep; 85(17):9078-89. PubMed ID: 21715480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short Communication: The Broad-Spectrum Histone Deacetylase Inhibitors Vorinostat and Panobinostat Activate Latent HIV in CD4(+) T Cells In Part Through Phosphorylation of the T-Loop of the CDK9 Subunit of P-TEFb.
    Jamaluddin MS; Hu PW; Jan Y; Siwak EB; Rice AP
    AIDS Res Hum Retroviruses; 2016 Feb; 32(2):169-73. PubMed ID: 26727990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Archin NM; Liberty AL; Kashuba AD; Choudhary SK; Kuruc JD; Crooks AM; Parker DC; Anderson EM; Kearney MF; Strain MC; Richman DD; Hudgens MG; Bosch RJ; Coffin JM; Eron JJ; Hazuda DJ; Margolis DM
    Nature; 2012 Jul; 487(7408):482-5. PubMed ID: 22837004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The histone deacetylase inhibitor vorinostat (SAHA) increases the susceptibility of uninfected CD4+ T cells to HIV by increasing the kinetics and efficiency of postentry viral events.
    Lucera MB; Tilton CA; Mao H; Dobrowolski C; Tabler CO; Haqqani AA; Karn J; Tilton JC
    J Virol; 2014 Sep; 88(18):10803-12. PubMed ID: 25008921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histone methyltransferase inhibitors induce HIV-1 recovery in resting CD4(+) T cells from HIV-1-infected HAART-treated patients.
    Bouchat S; Gatot JS; Kabeya K; Cardona C; Colin L; Herbein G; De Wit S; Clumeck N; Lambotte O; Rouzioux C; Rohr O; Van Lint C
    AIDS; 2012 Jul; 26(12):1473-82. PubMed ID: 22555163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo analysis of the effect of panobinostat on cell-associated HIV RNA and DNA levels and latent HIV infection.
    Tsai P; Wu G; Baker CE; Thayer WO; Spagnuolo RA; Sanchez R; Barrett S; Howell B; Margolis D; Hazuda DJ; Archin NM; Garcia JV
    Retrovirology; 2016 May; 13(1):36. PubMed ID: 27206407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells.
    Fiskus W; Pranpat M; Balasis M; Herger B; Rao R; Chinnaiyan A; Atadja P; Bhalla K
    Mol Cancer Ther; 2006 Dec; 5(12):3096-104. PubMed ID: 17172412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantification of HIV-1 latency reversal in resting CD4+ T cells from patients on suppressive antiretroviral therapy.
    Cillo AR; Sobolewski MD; Bosch RJ; Fyne E; Piatak M; Coffin JM; Mellors JW
    Proc Natl Acad Sci U S A; 2014 May; 111(19):7078-83. PubMed ID: 24706775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells.
    Knutson SK; Wigle TJ; Warholic NM; Sneeringer CJ; Allain CJ; Klaus CR; Sacks JD; Raimondi A; Majer CR; Song J; Scott MP; Jin L; Smith JJ; Olhava EJ; Chesworth R; Moyer MP; Richon VM; Copeland RA; Keilhack H; Pollock RM; Kuntz KW
    Nat Chem Biol; 2012 Nov; 8(11):890-6. PubMed ID: 23023262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non-small-cell lung cancer cells.
    Takashina T; Kinoshita I; Kikuchi J; Shimizu Y; Sakakibara-Konishi J; Oizumi S; Nishimura M; Dosaka-Akita H
    Cancer Sci; 2016 Jul; 107(7):955-62. PubMed ID: 27116120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid.
    Archin NM; Espeseth A; Parker D; Cheema M; Hazuda D; Margolis DM
    AIDS Res Hum Retroviruses; 2009 Feb; 25(2):207-12. PubMed ID: 19239360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latency.
    Archin NM; Kirchherr JL; Sung JA; Clutton G; Sholtis K; Xu Y; Allard B; Stuelke E; Kashuba AD; Kuruc JD; Eron J; Gay CL; Goonetilleke N; Margolis DM
    J Clin Invest; 2017 Aug; 127(8):3126-3135. PubMed ID: 28714868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-Activity Relationship Studies for Enhancer of Zeste Homologue 2 (EZH2) and Enhancer of Zeste Homologue 1 (EZH1) Inhibitors.
    Yang X; Li F; Konze KD; Meslamani J; Ma A; Brown PJ; Zhou MM; Arrowsmith CH; Kaniskan HÜ; Vedadi M; Jin J
    J Med Chem; 2016 Aug; 59(16):7617-33. PubMed ID: 27468126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Entinostat is a histone deacetylase inhibitor selective for class 1 histone deacetylases and activates HIV production from latently infected primary T cells.
    Wightman F; Lu HK; Solomon AE; Saleh S; Harman AN; Cunningham AL; Gray L; Churchill M; Cameron PU; Dear AE; Lewin SR
    AIDS; 2013 Nov; 27(18):2853-62. PubMed ID: 24189584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Small Molecule Inhibitors of BAF; A Promising Family of Compounds in HIV-1 Latency Reversal.
    Stoszko M; De Crignis E; Rokx C; Khalid MM; Lungu C; Palstra RJ; Kan TW; Boucher C; Verbon A; Dykhuizen EC; Mahmoudi T
    EBioMedicine; 2016 Jan; 3():108-121. PubMed ID: 26870822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of Ezh2 In Vitro and the Decline of
    Hong F; Zhao M; Zhang L; Feng L
    Stem Cells Dev; 2019 May; 28(10):649-658. PubMed ID: 30887911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NF-kappaB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation.
    Williams SA; Chen LF; Kwon H; Ruiz-Jarabo CM; Verdin E; Greene WC
    EMBO J; 2006 Jan; 25(1):139-49. PubMed ID: 16319923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.